SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- BeLive Studios, NewUnivers and ChopChop Systems executed a Memorandum of Understanding (MOU) at the Asia TV Forum and Market (ATF) today. The MOU establishes a strategic framework for collaboration among the three parties in the production, co-production and operational integration of microdrama content.
The partnership was initiated through Content IP Xcelerate in Singapore, operated by the Korea Creative Content Agency (KOCCA) Singapore Business Centre, and formally presented during KOCCA's participation at ATF. The signing ceremony was conducted in the presence of government and industry representatives from Korea and Singapore.
Under the MOU, the parties will explore coordinated development of microdrama projects, including the potential production of more than 50 titles over a twelve month period. The collaboration also includes developing a content distribution ecosystem.
The scope covers end-to-end microdrama development including ideation, script development, casting, production, post production and distribution. The partnership further contemplates the integration of ChopChop Systems' workflow technology into BeLive's and NewUnivers' processes to support more efficient production operations.
About the Companies
BeLive Studios
BeLive Studios is the creative-tech subsidiary of BeLive Technology (NASDAQ: BLIV), a technology provider in interactive live and video commerce solutions. We combine cinematic storytelling with technology-driven innovation, positioning ourselves as a new-generation studio that builds, scales, and monetizes IP across microdramas, branded entertainment, and interactive formats.
NewUnivers Inc
Founded in 2024 by CEO Ryan Jeong, who previously served as the head of the first short-form drama company in Korea, NewUnivers was established with the conviction that microdramas would become the next major engine of the global entertainment content industry. NU aims to build the world's largest K-short-form drama production ecosystem, encompassing planning, production, distribution, and services, to connect K-creators and IP with the global 3.0 streaming video market.
Since its launch, NewUnivers has produced approximately 20 microdramas. Its title "Goodbye My Brothers" notably ranked No.1 in the global microdrama category upon its launch on the Dramawave platform. Positioned as an outstanding K-short drama producer in 2025, NewUnivers is slated to produce 60 titles in 2026 across various genres, solidifying its standing as a top-tier microdrama production company in the global market.
ChopChop Systems
ChopChop Systems provides workflow solutions for media professionals, filmmakers and content creators. As demand for faster video production grows, the company fills a crucial gap in the industry with its automated post-production workflows, helping creators deliver more stories, faster. ChopChop's solutions save production teams hundreds of hours every year, allowing them to hit deadlines while preserving their well-being.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "potential production," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the expected trading of its Ordinary Shares on the Nasdaq Capital Market and the closing of the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
|
NEW YORK, March 3, 2026 /PRNewswire/ -- IOPE, a clinical-grade skincare brand from Amorepacific and a leader in Korean anti-aging innovation, officially debuts in the U.S. market today. Backed by 30 years of research and expertise in Korea, the United States marks the brand's second global market through strategic retail partnerships at Sephora. IOPE launches on Sephora.com today, rolling out to Sephora stores later in the month.
"We are thrilled to bring IOPE to the U.S. after decades of unparallelled performance in Korea," said Giovanni Valentini, CEO Amorepacific North America. "Consumers are more discerning than ever, prioritizing clinically proven efficacy and visible results in an increasingly saturated skincare market. With IOPE, we are introducing targeted skincare solutions, that are clinically tested, at a competitive price point."
For three decades, IOPE has been at the forefront of Korean anti-aging research, grounded in rigorous clinical testing. The brand has pioneered advancements in key active ingredients, including PDRN, stabilized Vitamin C, and innovative retinol stabilization technology that is supported by 26 Korean patents and more than a dozen scientific publications. As Korean skincare continues to set the global standard for innovation and performance, IOPE stands among the category's most respected leaders.
IOPE's professional treatment–inspired formulations are rooted in evidence-based research and designed to deliver visible improvements across key skin concerns, including texture, firmness, brightness, and overall vitality, redefining expectations for at-home skincare performance.
IOPE enters the U.S. market with nine targeted products, featuring the brand's transformative XMD, Retinol RX™, Vitamin C, and PDRN Caffeine collections. Their newest innovations draw inspiration from Korea's viral skin booster treatments and are clinically proven to deliver professional treatment-level results at home:
- XMD Stem III Clinical Recovery Serum ($59): Inspired by Korea's viral professional PDRN treatments, this advanced serum was clinically tested to deliver professional PDRN treatment–level results across six key metrics, including increased volume, improved elasticity, and enhanced texture – without the downtime or discomfort associated with in-office treatments. The breakthrough formula is powered by 92.3% PDRN H.A.™ Liposome Complex, featuring PDRN, micro-molecular hyaluronic acid, and a soothing allantoin-based complex.
- Retinol RX™ 2% Reti-jection™ Serum ($57): Formulated with a 2% concentration of Retinol RX™ – IOPE's proprietary retinoid complex – this high-performance serum is designed to optimize efficacy while reducing irritation. The formula features retinol-infused spicules to enhance absorption. The serum is clinically proven to deliver collagen booster treatment–level results, including reduced look of wrinkles, minimized pore appearance, and enhanced radiance.
IOPE products range in price from $6.50 for a single sheet mask to $69 for XMD Stem III Clinical Recovery Cream.
IOPE is available now at Sephora.com and will be available in Sephora stores nationwide starting March 13, 2026.
About AMOREPACIFIC:
Established in 1945, Amorepacific is Korea's leading beauty company, powered by a global portfolio of category defining skincare, makeup, haircare, and wellness brands. Rooted in pioneering research that began with Korea's first cosmetics lab, the company continues to shape the future of K-beauty through bio-driven, longevity-focused innovation.
NEW YORK, March 3, 2026 /PRNewswire/ -- IOPE, a clinical-grade skincare brand from Amorepacific and a leader in Korean anti-aging innovation, officially debuts in the U.S. market today. Backed by 30 years of research and expertise in Korea, the United States marks the brand's second global market through strategic retail partnerships at Sephora. IOPE launches on Sephora.com today, rolling out to Sephora stores later in the month.
"We are thrilled to bring IOPE to the U.S. after decades of unparallelled performance in Korea," said Giovanni Valentini, CEO Amorepacific North America. "Consumers are more discerning than ever, prioritizing clinically proven efficacy and visible results in an increasingly saturated skincare market. With IOPE, we are introducing targeted skincare solutions, that are clinically tested, at a competitive price point."
For three decades, IOPE has been at the forefront of Korean anti-aging research, grounded in rigorous clinical testing. The brand has pioneered advancements in key active ingredients, including PDRN, stabilized Vitamin C, and innovative retinol stabilization technology that is supported by 26 Korean patents and more than a dozen scientific publications. As Korean skincare continues to set the global standard for innovation and performance, IOPE stands among the category's most respected leaders.
IOPE's professional treatment–inspired formulations are rooted in evidence-based research and designed to deliver visible improvements across key skin concerns, including texture, firmness, brightness, and overall vitality, redefining expectations for at-home skincare performance.
IOPE enters the U.S. market with nine targeted products, featuring the brand's transformative XMD, Retinol RX™, Vitamin C, and PDRN Caffeine collections. Their newest innovations draw inspiration from Korea's viral skin booster treatments and are clinically proven to deliver professional treatment-level results at home:
- XMD Stem III Clinical Recovery Serum ($59): Inspired by Korea's viral professional PDRN treatments, this advanced serum was clinically tested to deliver professional PDRN treatment–level results across six key metrics, including increased volume, improved elasticity, and enhanced texture – without the downtime or discomfort associated with in-office treatments. The breakthrough formula is powered by 92.3% PDRN H.A.™ Liposome Complex, featuring PDRN, micro-molecular hyaluronic acid, and a soothing allantoin-based complex.
- Retinol RX™ 2% Reti-jection™ Serum ($57): Formulated with a 2% concentration of Retinol RX™ – IOPE's proprietary retinoid complex – this high-performance serum is designed to optimize efficacy while reducing irritation. The formula features retinol-infused spicules to enhance absorption. The serum is clinically proven to deliver collagen booster treatment–level results, including reduced look of wrinkles, minimized pore appearance, and enhanced radiance.
IOPE products range in price from $6.50 for a single sheet mask to $69 for XMD Stem III Clinical Recovery Cream.
IOPE is available now at Sephora.com and will be available in Sephora stores nationwide starting March 13, 2026.
About AMOREPACIFIC:
Established in 1945, Amorepacific is Korea's leading beauty company, powered by a global portfolio of category defining skincare, makeup, haircare, and wellness brands. Rooted in pioneering research that began with Korea's first cosmetics lab, the company continues to shape the future of K-beauty through bio-driven, longevity-focused innovation.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
IOPE LAUNCHES IN THE U.S.
